Meeting
2013 Gastrointestinal Cancers Symposium
A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.
Authors
Yung-Jue Bang
Seoul National University Hospital, Seoul National
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT00486954
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr11)
DOI
10.1200/jco.2013.31.4_suppl.11
Abstract #
11
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.
First Author: Guo-ping Sun
Poster
2018 ASCO Annual Meeting
Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.
First Author: Tomomi Kashiwada
Poster
2024 ASCO Annual Meeting
Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.
First Author: Jin Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price